⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABBV News
ABBVIE INC.
Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma
globenewswire.com
ABBV
ARCC
GSK
JNJ
REGN
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
globenewswire.com
LUN
LLY
AMGN
NVS
TEVA
ALLER
BHVN
DRREDDY
ABBV
IMPL
ZSAN
AXSM
AEON
IONS
CHRC
AZN
GSK
WSTN
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
prnewswire.com
ABBV
À l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de
prnewswire.com
ABBV
AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegen USA - Deutsch USA - English
prnewswire.com
ABBV
Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
prnewswire.com
AGN
NOVN
EXEL
ABBV
BMY
EISAY
TKPY
MRK
AbbVie presentará datos de fase 3 de ECLIPSE en el 19º Congreso Europeo de Cefaleas USA - español USA - English
prnewswire.com
ABBV
Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
prnewswire.com
ABBV
GILD
BMY
REGN
XBI
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
prnewswire.com
ABBV
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
globenewswire.com
ABBV